Nanogen Announces Patent for Fluorescent Detection of Nucleic Acid Targets
News Oct 13, 2005
Nanogen, Inc. has announced that its subsidiary, Epoch Biosciences, was issued Patent No. 6,951,930, "Hybridization-Triggered Fluorescent Detection of Nucleic Acids" by the U.S. Patent and Trademark Office.
The '930 patent relates to latent fluorophore-minor groove binder oligonucleotide conjugates which fluoresce upon hybridization to a target.
The conjugates may be used to detect nucleic acid targets. The technology described in the patent also allows for simpler and faster fluorescent real-time molecular analyses.
Sensitive and specific detection of nucleic acid targets play an integral role in any molecular application, including infectious and genetic disease diagnostics.
Using the latent fluorescent-minor groove binder oligonucleotide conjugates, with low fluorescing backgrounds, either as primers or probes, can create improved diagnostic reagents.
These reagents contain shorter highly conserved sequence regions improving assay specificity, and the probes are non-cleavable which allows post-PCR melt curve analysis.
"Nanogen and the Epoch researchers are continually discovering methods to improve the sensitivity and specificity of detection for nucleic acid targets related to disease," said Howard C. Birndorf, Nanogen chairman and chief executive officer.
"Nanogen's MGB™ products that incorporate this improved, fluorescent target detection technology are well recognized by many researchers and diagnostic labs as the standard for real-time PCR probe and primer technology."
"Our strong intellectual property and technology development capabilities will allow us to bring highly valued molecular diagnostic products to the market and our partners and ultimately help change healthcare practices."
Herpesvirus and Alzheimer's Link: High abundance of Herpes genes in postmortem Alzheimer's brain tissueNews
Data from three different brain banks to suggest that human herpesviruses are more abundant in the brains of Alzheimer's patients and may play a role in regulatory genetic networks that are believed to lead to the disease.READ MORE
Gene-edited Pigs are Resistant to Billion-dollar VirusNews
Scientists have produced pigs that can resist one of the world’s most costly animal diseases, by changing their genetic code. Tests with the virus – called Porcine Reproductive and Respiratory Syndrome, or PRRS – found the pigs do not become infected at all. The animals show no signs that the change in their DNA has had any other impact on their health or wellbeing.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE